LGALS3 and congestive heart failure: It is yet unclear whether Gal-3 is influenced or not by other biomarkers, as suggested by the study performed by Miller et al., in which Gal-3 proved to be a predictor of cardiac adverse events in CHF patients only in conjunction with ST2 and not taken individually [79].